Gritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Potential Role of Its Personalized Cancer Vaccine, GRANITE, in Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Core Insights - Gritstone bio, Inc. is hosting a virtual key opinion leader event on August 2, 2024, focusing on the treatment landscape for metastatic microsatellite stable colorectal cancer (MSS-CRC) [1] - The event will feature Dr. J. Randolph Hecht and Howard Brown, who will discuss the unmet needs in MSS-CRC treatment [1] - Gritstone is advancing its personalized neoantigen vaccine program, GRANITE, targeting immunologically "cold" tumors like MSS-CRC, with mature progression-free survival data expected in Q3 2024 [2] Company Overview - Gritstone bio, Inc. is a clinical-stage biotechnology company focused on developing potent vaccines to improve patient outcomes and eliminate diseases [6] - The company utilizes innovative vectors and payloads to engage multiple arms of the immune system against critical disease targets [6]